Hesham Mohamed

Title: The Innovative Contributions of Hesham Mohamed

Introduction

Hesham Mohamed is a notable inventor based in Watertown, MA (US). He has made significant contributions to the field of cancer treatment through his innovative research and patent work. His focus on androgen receptor-driven cancers has the potential to impact many lives.

Latest Patents

Hesham Mohamed holds a patent for "Bromodomain inhibitors for androgen receptor-driven cancers." This patent discloses methods for treating certain androgen receptor-positive forms of cancer using inhibitors of the CREB binding protein bromodomain. The methods outlined in the patent may be applicable to various forms of cancer, including breast cancer and prostate cancer. Specifically, the patent addresses treatment methods for AR-positive forms of cancer, including triple-negative breast cancer and metastatic castration-resistant prostate cancer. One of the compounds mentioned in the patent is (1R,3R)-3-[(7S)-2-[(R)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid, or a pharmaceutically acceptable salt thereof.

Career Highlights

Hesham Mohamed is currently employed at Forma Therapeutics, Inc., where he continues to advance his research in cancer therapies. His work is characterized by a commitment to developing innovative solutions for challenging medical conditions.

Collaborations

Hesham collaborates with talented professionals in his field, including Sylvie Guichard and Maureen Caligiuri. These collaborations enhance the research environment and contribute to the development of effective cancer treatments.

Conclusion

Hesham Mohamed's contributions to cancer research through his patent on bromodomain inhibitors exemplify the impact of innovation in medicine. His work at Forma Therapeutics, Inc. and collaborations with esteemed colleagues further highlight his dedication to improving patient outcomes.